Drug intelligence / Profile preview

taraxacum officinale pollen + helianthus annuus pollen + leucanthemum vulgare pollen

Development stage
Approved
Lead developer
Stallergenes Greer
Administration
Percutaneous, Intradermal, Subcutaneous
01

Overview

This product is a **combination allergenic extract biologic** composed of non-standardized pollen extracts from *Taraxacum officinale* (dandelion), *Helianthus annuus* (sunflower), and *Leucanthemum vulgare* (daisy). It has been manufactured and distributed by Greer Laboratories and is used in allergy practice for **skin test diagnosis** and **allergen immunotherapy** in patients with clinically relevant sensitization to these pollens. Its pharmacologic effect is immunologic rather than receptor-selective: diagnostically, it is intended to detect allergen-specific immediate hypersensitivity, and therapeutically, repeated exposure is intended to modulate IgE-mediated allergic responses and reduce allergen-induced symptoms in appropriately selected patients. The product was initially approved in the United States in 1968 as part of the allergenic extract category.

Other names
taraxacum officinale pollen + helianthus annuus pollen + leucanthemum vulgare pollendandelion pollen + sunflower pollen + daisy pollentaraxacum officinale + helianthus annuus + leucanthemum vulgare allergenic extract
02

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on taraxacum officinale pollen + helianthus annuus pollen + leucanthemum vulgare pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on taraxacum officinale pollen + helianthus annuus pollen + leucanthemum vulgare pollen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call